No Mid-Term Revision Of Stent Prices Before February 2018, Says Drug Pricing Regulator
Drug pricing regulator NPPA on Friday ruled out mid-term revision of coronary stent prices, saying it would revisit the matter in February 2018 after taking into consideration all related issues.
In February this year, the National Pharmaceutical Pricing Authority (NPPA) had reduced prices of coronary stents by up to 85 percent, capping them at Rs 7,260 for bare metal ones, and Rs 29,600 for the drug eluting variety, giving a major relief to patients.
The maximum retail price of a stent prior to the price cap ranged from Rs 25,000 to Rs 1.98 lakh. Stent manufacturers had stated the step would lead to non-availability of advanced forms of the medical device due to pricing issues.
“NPPA will revisit the prices of coronary stents in February 2018,” the regulator said a tweet.
NPPA will revisit the prices of coronary stents in Feb, 2018 taking into account all the issues; no mid term revision in prices before that
September 15, 2017Earlier in April, the government had rejected applications by multinational firms Abbott and Medtronic seeking withdrawal of their advanced coronary stents from India and asked them to maintain supplies of the products.
In a notification at that time, NPPA had asked the companies to consider options for price revision before deciding to withdraw their products from the market.
Also Read: Stent Price Cap Turns Away The Rich Patient On Whom Healthcare Survives: Devi Shetty
While capping the price of the stents, government had made it mandatory for stent makers to maintain production and supply of coronary stents by invoking an emergency clause under drug price control law citing reports of shortage in market.
The move of capping the prices of stents was opposed by medical device makers at that time, with CII Medical Technology Division Chairman Himanshu Baid stating that the “move could limit the accessibility of cutting-edge technologies in coronary stents for Indian patients, affecting both treatment quality and risking the high growth medical tourism sector”.
A coronary stent is a tube-shaped device placed in the arteries that supply blood to the heart. It keeps the arteries open in the treatment of coronary heart diseases.
Also Read: After Coronary Stents, Regulator Caps Prices Of Knee Implants
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
